« BackNanomedicine: Nanotechnology, Biology and Medicine
Article in Press

Development and evaluation of a dual-modality (MRI/SPECT) molecular imaging bioprobe

  • Ripen Misri, PhD

      Affiliations

    • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
    • ,
  • Dominik Meier, PhD

      Affiliations

    • Dept. of Radiology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
    • ,
  • Andrew C. Yung, MSE

      Affiliations

    • MRI Research Centre, Physics Department, University of British Columbia, Vancouver, Canada
    • ,
  • Piotr Kozlowski, PhD

      Affiliations

    • MRI Research Centre, Physics Department, University of British Columbia, Vancouver, Canada
    • ,
  • Urs O. Häfeli, PhD

      Affiliations

    • Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada
    • Corresponding Author InformationCorresponding author: Faculty of Pharmaceutical Sciences, University of British Columbia, 2146 East Mall, Vancouver, BC V6T 1Z3, Canada.

Received 21 July 2011; accepted 24 October 2011. published online 17 November 2011.
Corrected Proof

Abstract 

Specific bioprobes for single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) have enormous potential for use in cancer imaging in near-future clinical settings. The authors describe the development of dual modality molecular imaging bioprobes, in the form of magnetic nanoparticles (NPs) conjugated to antibodies, for SPECT and MRI of mesothelin-expressing cancers. The bioprobes were developed by conjugating 111In labeled antimesothelin antibody mAbMB to superparamagnetic iron oxide NPs. Our experimental findings provide evidence that such bioprobes retain their magnetic properties as well as the ability to specifically localize in mesothelin-expressing tumors. It is anticipated that combining SPECT with MR will help obtain both functional and anatomical imaging information with high signal sensitivity and contrast, thereby providing a powerful diagnostic tool for early diagnosis and treatment planning of mesothelin-expressing cancers.

Graphical Abstract 

A molecular imaging agent comprising magnetic nanoparticles bioconjugated to radioactive antibodies was developed for dual-modality imaging of tumors with SPECT and MRI. This dual-modality imaging approach is advantageous due to the ability of each imaging modality to image different properties or processes, allowing more precise localization of the tumors.

Key words: MRI, SPECT, Imaging, Dual modality, Nanoparticles

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 No conflict of interest was reported by the authors of this article.

 This project was funded by a Discovery Grant awarded to UOH by the Natural Sciences and Engineering Research Council of Canada (NSERC).

PII: S1549-9634(11)00521-1

doi:10.1016/j.nano.2011.10.013

« BackNanomedicine: Nanotechnology, Biology and Medicine

Article Tools

* Image Usage & Resolution